Analyst Ratings For Sorrento Therapeutics (NASDAQ:SRNE)
Today, HC Wainwright reiterated its Buy rating on Sorrento Therapeutics (NASDAQ:SRNE) with a price target of $35.00.
Some recent analyst ratings include
- 2/20/2018-HC Wainwright Reiterated Rating of Buy.
- 1/19/2018-Oppenheimer Reiterated Rating of Buy.
- 8/3/2017-Roth Capital initiated coverage with a Buy rating.
- 6/17/2017-FBR & Co Reiterated Rating of Buy.
- 8/12/2016-Brean Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For Sorrento Therapeutics (NASDAQ:SRNE)
Sorrento Therapeutics (NASDAQ:SRNE) has insider ownership of 5.00% and institutional ownership of 12.32%.
- On 2/7/2018 Abg Management Ltd, Major Shareholder, sold 150,000 with an average share price of $7.19 per share and the total transaction amounting to $1,078,500.00.
- On 2/5/2018 Abg Management Ltd, Major Shareholder, sold 70,721 with an average share price of $8.00 per share and the total transaction amounting to $565,768.00.
- On 1/30/2018 Abg Management Ltd, Major Shareholder, sold 310,000 with an average share price of $7.64 per share and the total transaction amounting to $2,368,400.00.
- On 1/24/2018 Pacific Medtech (Bvi) Ltd Asia, Major Shareholder, sold 684,288 with an average share price of $7.56 per share and the total transaction amounting to $5,173,217.28.
- On 6/15/2017 Henry Ji, Insider, bought 29,001 with an average share price of $1.81 per share and the total transaction amounting to $52,491.81.
- On 6/15/2017 Jaisim Shah, Director, bought 10,002 with an average share price of $1.79 per share and the total transaction amounting to $17,903.58.
- On 4/19/2017 Abg Management Ltd, Major Shareholder, bought 550,000 with an average share price of $2.00 per share and the total transaction amounting to $1,100,000.00.
Recent Trading Activity for Sorrento Therapeutics (NASDAQ:SRNE)
Shares of Sorrento Therapeutics closed the previous trading session at 9.05 up +0.30 3.43% with 9.25 shares trading hands.